Ionis Pharmaceuticals Overview

  • Status
  • Public
  • Employees
  • 660
Employees
  • Stock Symbol
  • IONS
Stock Symbol
  • Investments
  • 19
  • Share Price
  • $36.86
  • (As of Wednesday Closing)

Ionis Pharmaceuticals General Information

Description

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Contact Information

Formerly Known As
Isis Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 2855 Gazelle Court
  • Carlsbad, CA 92010
  • United States
+1 (760) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ionis Pharmaceuticals Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$36.86 $37.11 $25.04 - $44.42 $5.26B 142M 1.08M -$0.02

Ionis Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 4,384,227 3,616,659 6,620,295 7,112,637
Revenue 840,768 810,456 729,264 1,122,599
EBITDA 18,810 (5,288) (111,192) 367,200
Net Income (3,893) (28,597) (444,263) 278,143
Total Assets 2,519,092 2,611,690 2,389,755 3,233,112
Total Debt 1,222,220 1,251,050 939,639 787,526
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ionis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ionis Pharmaceuticals‘s full profile, request access.

Request a free trial

Ionis Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad cl
Drug Discovery
Carlsbad, CA
660 As of 2021
0000
0.000 0000-00-00
00000000000 0000

00000000

olor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint
0000000000000
Pasadena, CA
000 As of 0000
00.000
000000 - 000 00.000

0000000

por incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000 000000000
Cambridge, MA
0000 As of 0000
00.00
00000000000 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ionis Pharmaceuticals Competitors (45)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arrowhead Pharmaceuticals Corporation Pasadena, CA 000 00.000 000000 - 000 00.000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.00 00000000000 00.00
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
000000000 00000000 Formerly VC-backed San Diego, CA 000 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 0000 00.000 0000 00.000
You’re viewing 5 of 45 competitors. Get the full list »

Ionis Pharmaceuticals Patents

Ionis Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210139906-A1 Compounds and methods for reducing spdef expression Pending 08-Nov-2019 000000000
US-20210038629-A1 Compounds and methods for modulating gfap Pending 26-Jul-2019 00000000000
US-20210277397-A1 Compounds and methods for modulating ube3a-ats Pending 29-Mar-2019 0000000000
AU-2020253821-A1 Compounds and methods for modulating ube3a-ats Pending 29-Mar-2019 0000000000
CA-3135180-A1 Compounds and methods for modulating ube3a-ats Pending 29-Mar-2019 C12N15/113
To view Ionis Pharmaceuticals’s complete patent history, request access »

Ionis Pharmaceuticals Executive Team (21)

Name Title Board Seat Contact Info
Brett Monia Ph.D Chief Executive Officer & Board Member
Elizabeth Hougen Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
C. Bennett Ph.D Chief Scientific Officer & Executive Vice President
Frank Bennett Ph.D Chief Scientific Officer & Executive Vice President
Morgan Schapiro Director Business Development & Head of External Innovation
You’re viewing 5 of 21 executive team members. Get the full list »

Ionis Pharmaceuticals Board Members (12)

Name Representing Role Since
000000 0000 Self Board Member 000 0000
0. 00000000 000 Ionis Pharmaceuticals Board Member & Executive 000 0000
00000 00000 00.0 Ionis Pharmaceuticals Chief Executive Officer & Board Member 000 0000
000000000 0000 00 Self Board Member 000 0000
0000 000000 Self Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Ionis Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ionis Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ionis Pharmaceuticals‘s full profile, request access.

Request a free trial

Ionis Pharmaceuticals Investments & Acquisitions (19)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000 23-Nov-2021 00000 0000 000.00 Biotechnology
00000 0000000 12-Oct-2020 0000000000 00000 Biotechnology 00000 000
00000000 24-Dec-2019 00000 0000 0000 Biotechnology
00000000 10-Nov-2017 00000 0000 Drug Discovery 00000 000
YourBio Health 06-Sep-2017 Later Stage VC 00.00 Other Devices and Supplies 0. 000000
You’re viewing 5 of 19 investments and acquisitions. Get the full list »

Ionis Pharmaceuticals Exits (10)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 0000000000 04-Oct-2012 000 0000 Completed
  • 3 buyers
000000 00000000000 12-Nov-2009 00000 00000 00 0000 Completed
  • 5 buyers
0000000 0000000000 04-Mar-2009 00000 00000 00 0000 Completed
  • 2 buyers
000 000000000000 09-Feb-2009 0000 00.00 Completed
  • 00000 000000000000
ICO Therapeutics 31-Dec-2007 Early Stage VC 0000 Completed
You’re viewing 5 of 10 exits. Get the full list »